Sleepypod Rebrands as Paw Prosper Builds Out Its Pet-Health Family
Sleepypod launched a new identity and website under the line "Protecting What Matters," deepening its alignment with parent Paw Prosper, the Denver company assembling a portfolio of specialty pet-health brands. Sleepypod anchors the family's safety and prevention category.
Crash-tested pet travel just got a refresh. Sleepypod, the safety brand known for its crash-certified carriers and harnesses, rolled out a new identity and website this week under the line “Protecting What Matters,” tightening its alignment with parent company Paw Prosper.
Paw Prosper is standardizing a brand it bought 18 months ago
Sleepypod launched a redesigned site built around safety education, product-testing content, and survivor accounts from real car-crash cases.
The brand pioneered a family of 13 data-collecting crash-test dummies that span different species, sizes, and body builds, using instrumented sensors to measure g-force and point-of-view cameras to capture collision dynamics.
Since 2008 it has paired that lab work with real-world accident data through its Crash Replacement Program, and reports zero crash-related injuries for pets secured in its carriers and car harnesses. That crash-test rigor is the brand’s real moat, the reason it stands apart in a category where most pet restraints are never independently tested at all.
Founded in 2005 in Pasadena, Sleepypod was acquired by Paw Prosper in January 2025. The rebrand explicitly aligns it with the parent, routing customers and pet professionals into Paw Prosper’s hub for wellness, rehabilitation, aging support, pain prevention, and mobility.
“This rebrand is not a departure from Sleepypod’s heritage, but a sharper focus on the rigorous testing, purposeful engineering, and an unwavering promise to protect pets like family,” said Ryan DeCaire, CEO of Paw Prosper.
How Sleepypod fits Paw Prosper’s growing family of brands
Paw Prosper, the Denver company that acquired Sleepypod in January 2025, has spent three years assembling a portfolio of specialty pet-health brands: Help ’Em Up, FitPAWS, Muffin’s Halo, Respond Systems, Walkin’ Pets, Blue-9, and Dr. Buzby’s ToeGrips, plus the Canine Rehabilitation Institute this January. The rebrand brings Sleepypod’s look and digital experience into that family.
Within it, Sleepypod owns prevention. Its crash-test certification and zero-injury record make it the safety anchor of a portfolio otherwise built around rehab, mobility, and aging support. For a platform focused on keeping pets healthy across every life stage, a trusted travel-safety brand is a natural front door.
What the rebrand signals next
A company that closed a rehab-education acquisition in January and is refreshing portfolio brands through mid-2026 is clearly still building. The direction is unmistakable: a well-capitalized platform is assembling a full-lifecycle pet-health catalog, and it is willing to pay up for category-defining brands to anchor it.
Source: This news brief is based on a company-submitted announcement. The Underbite verifies claims where possible but cannot independently confirm all details.
Other News
More stories shaping the pet industry this week. From funding rounds and product launches to regulatory shifts and retail strategy, stay ahead of what's driving the market.
Vetspire Splits From Thrive, Lands a Battery Ventures Backing
Vetspire has spun out of Thrive Pet Healthcare's orbit with a growth investment from Battery Ventures and a new CEO, Zachary Seely. The AI-powered practice management platform, used by more than 800 veterinary hospitals and clinics, will operate independently while Thrive remains a customer. The deal tests whether AI-native vet software can draw institutional capital without a strategic parent underwriting it.
PetMeds Revenue Falls 20% as Takeover Fight Drags On
PetMeds' first-quarter revenue fell 19.9% to $41.0 million and cash reserves dropped to $13.1 million, even as the company narrowed its net loss to $6.1 million from $34.2 million a year earlier. The results land as an unsolicited $3-a-share buyout offer from SilverCape Investments remains on the table and a $37 million sale-leaseback of its headquarters awaits closing.
FDA Clears Zoetis Drug for Screwworm as Outbreak Spreads North
The FDA granted Zoetis an emergency use authorization for Simparica Trio to treat New World screwworm in dogs, the first product cleared specifically for the threat. Texas has already begun requiring treatment before dogs cross certain lines, putting boarding facilities, transporters, and border-state vet practices under a new compliance mandate.